Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

744.44 UNCHANGED

Streaming Delayed Price Updated: 4:15 PM EDT, Apr 27, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,571
Open	744.44
Bid (Size)	748.65 (40)
Ask (Size)	752.00 (80)
Prev. Close	744.44
Today's Range	744.44 - 744.44
52wk Range	476.49 - 821.11
Shares Outstanding	91,779,465
Dividend Yield	0.51%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Regeneron (REGN) Q1 Earnings Report Preview: What To Look For

April 27, 2026

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Wednesday morning. Here’s what to expect. Regeneron beat analysts’ revenue expectatio...

Via StockStory

These S&P500 stocks are gapping in today's session ↗

April 24, 2026

Via Chartmill

Performance

YTD	-4.1%	-4.1%
1 Month	-0.6%	-0.6%
3 Month	-2.4%	-2.4%
6 Month	+27.2%	+27.2%
1 Year	+21.9%	+21.9%

More News

Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

April 23, 2026

Via StockStory

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

April 23, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Pharmaceuticals (NASDAQ:REGN) Emerges as a 'Decent Value' Biotech Pick ↗

April 21, 2026

Via Chartmill

Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.

April 23, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

April 22, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth ↗

April 21, 2026

Via The Motley Fool

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

April 21, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces Investor Conference Presentations

April 20, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky

April 20, 2026

Via StockStory

3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗

April 18, 2026

Via The Motley Fool

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

Via The Motley Fool

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

Via Finterra

Telix and Regeneron Announce Strategic Radiopharma Collaboration

April 13, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Regeneron and Telix Announce Strategic Radiopharma Collaboration

April 13, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

April 13, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron (REGN): Buy, Sell, or Hold Post Q4 Earnings?

April 10, 2026

Via StockStory

Productivity Surge and Falling Jobless Claims: The New U.S. Labor Paradigm

April 06, 2026

Via MarketMinute

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

April 03, 2026

Via Finterra

Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

April 02, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

April 02, 2026

Via StockStory

EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

April 02, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

Via MarketMinute

Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena ↗

March 30, 2026

Via The Motley Fool

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?

Yes, Regeneron Pharmaceuticals is publicly traded.

What exchange does Regeneron Pharmaceuticals trade on?

Regeneron Pharmaceuticals trades on the Nasdaq Stock Market

What is the ticker symbol for Regeneron Pharmaceuticals?

The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market

What is the current price of Regeneron Pharmaceuticals?

The current price of Regeneron Pharmaceuticals is 744.44

When was Regeneron Pharmaceuticals last traded?

The last trade of Regeneron Pharmaceuticals was at 04/27/26 04:15 PM ET

What is the market capitalization of Regeneron Pharmaceuticals?

The market capitalization of Regeneron Pharmaceuticals is 68.32B

How many shares of Regeneron Pharmaceuticals are outstanding?

Regeneron Pharmaceuticals has 68B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.